Figure 3 from Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Year: 2024
Type: other
Abstract: STK11 co-mutation negates KRAS-induced immunogenicity. A, PDL1 TPS for all patients with NSCLC arranged by TP53 mutation status [N = 44 WT; N = 145 TP53-mutated (MT)]. B and C,CD274 mRNA expression or PDL1 TPS arranged by combined KRAS and TP53 mutation statuses (N = 26 KRAS-WT/TP53-WT, N = 18 KRAS-MT/TP53-WT, N = 118 KRAS-WT/TP53-MT, N = 27 KRAS-MT/TP53-MT). D, PDL1 TPS arranged by STK11 mutation status (N = 166 wild-type or WT, N = 23 STK11-mutated or MT). E and F,CD274 mRNA expression or PDL1 TPS arranged by combined KRAS and STK11 mutation statuses (N = 131 KRAS-WT/STK11-WT; N = 35 KRAS-MT/STK11-WT; N = 13 KRAS-WT/STK11-MT; N = 10 KRAS-MT/STK11-MT). G, Percent CD8+ T-cell infiltration arranged by KRAS mutation status. H, Percent CD8+ T-cell infiltration arranged by combined KRAS and TP53 mutation statuses. I, Percent CD8+ T-cell infiltration arranged by combined KRAS and STK11 mutation statuses.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402067659